Send to

Choose Destination
Open Heart. 2018 Jan 9;5(1):e000652. doi: 10.1136/openhrt-2017-000652. eCollection 2018.

Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction.

Author information

BHF Centre, School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
Drug Discovery, Omeros Corporation, Seattle, Washington, USA.
Department of Infection, Immunity and inflammation, University of Leicester, Leicester, UK.



Myocardial ischaemia-reperfusion injury is a major cause of mortality and morbidity in the developed world. Many approaches have been investigated to counteract the pathological consequences associated with acute myocardial infarction (AMI) and cardiac remodelling. It is accepted that inflammation, and therefore activation of the complement pathway, is a crucial step in the pathogenesis of this injury, and many attempts have been made to ameliorate the infarction and consequent dysfunction using anticomplement therapy, with mixed success. Recently, the lectin complement activation pathway involving the mannose-binding lectin-associated serine protease 2 (MASP-2) has been shown to be an important mediator of the inflammatory response in ischaemia/reperfusion injury in the heart. In this study, therefore, we aimed to investigate the feasibility of using monoclonal antibodies raised against MASP-2 in a murine model of AMI.


Mice were injected with anti-MASP-2 antibody or control 18 hours prior to experimental infarction by ligation of the left anterior descending coronary artery for 30 min followed by 120 min reperfusion. The developed infarct was measured, and blood was collected for analysis of lectin pathway functional activity.

Results and conclusions:

We found that mice treated with anti-MASP-2 antibody had smaller infarcts than those treated with control antibody. We believe this may represent a valuable step forward in the protection of the myocardium against ischaemia-reperfusion injury.


haemodynamics; inflammation; mouse; myocardial ischaemia and infarction (ihd)

Conflict of interest statement

Competing interests: JC and MM have no interest to declare. TD is an employee and stockholder of Omeros Corp. WS is a consultant and receives research support from Omeros Corp. This study was funded partly by Omeros Corp.

Supplemental Content

Full text links

Icon for BMJ Publishing Group Icon for PubMed Central
Loading ...
Support Center